juniordoctornotes.com






Approach to Undifferentiated Shock
Main Assessment Factors to Differentiate Shock Types
- Peripheral perfusion (as a measure of TPR)
- Heart rate
- Preload status using JVP, CVP, PPV or response to passive leg raise
Overview of RUSH Exam
- Heart: LV function, RV dilation, pericardial effusion/tamponade
- IVC: size and collapsibility (volume responsiveness)
- Lungs: B-lines (pulmonary oedema), pneumothorax (absence of sliding)
- Abdomen: free fluid (haemoperitoneum, ruptured AAA)
- Aorta: AAA
- Lower limbs: DVT (if PE suspected)
Can use the mnemonic HI-MAP (Heart, IVC, Morrison’s pouch, Aorta, Pneumothorax) or alternatively go in the approach of pump (heart), tank (IVC, Morison’s pouch), and pipes (aorta, DVT)

Approach to Undifferentiated Shock
Approach to Undifferentiated Shock





Noradrenaline
0.01-3 mcg/kg/min IV infusion (central line preferred)
First line vasopressor in distributive and most forms of shock
Predominantly α1 agonist with some β1 ⇒ ↑ SVR and mild ↑ HR/CO
Can be run peripherally short-term (forearm or antecubital) at low doses while CVC inserted
Metaraminol
Bolus: 0.5-2 mg IV PRN | Infusion: 15-30 mg in 500 mL at 15-60 mL/hr
Predominantly α1 agonist; also causes indirect noradrenaline release
Used widely in peri-operative setting and as bridge vasopressor pre-noradrenaline
Can be given peripherally; suitable in ward or theatre setting
Tachyphylaxis with prolonged use
Reflex bradycardia can occur - treat with atropine
Less titratable than noradrenaline infusion
Adrenaline
Anaphylaxis: 0.3-0.5 mg IM (thigh) | Shock infusion: 0.01-1 mcg/kg/min IV
Anaphylaxis: IM adrenaline (Epipen 0.3 mg or ampoule 1:1000) is the drug of first choice
Septic shock: Second agent alongside noradrenaline when additional inotropic support needed; associated with increased lactate that does not reflect true worsening
Cardiogenic shock: Adrenaline has more arrhythmogenic risk than other inotropes
Cardiac arrest: 1 mg IV every alternate loop
Terlipressin
Bolus: 0.85–2.5 mg IV bolus q4–6h | Infusion: 1.3–5 mg/24h
- V1 receptor agonist (smooth muscle vasoconstriction)
- Hepatorenal syndrome type 1: terlipressin + albumin is first line
- Variceal bleeding: 2mg IV bolus then 1 mg q4-6h for up to 5 days
- Used in refractory septic shock as noradrenaline-sparing agent (off-label in Australia)
- Risk: digital/skin ischaemia, bradycardia, mesenteric ischaemia — monitor carefully
- Avoid in ischaemic heart disease, peripheral vascular disease
Dobutamine
2–20 mcg/kg/min IV infusion
- β1 and β2 agonist - positive inotropy, chronotropy; reduces SVR (vasodilatory)
- Used in cardiogenic shock with adequate MAP (often combined with noradrenaline)
- Risk of tachycardia and arrhythmia; may worsen hypotension in true hypovolaemia
Milrinone
0.125–0.75 mcg/kg/min IV (load: 25–50 mcg/kg over 10 min, often omitted)
- Used in cardiogenic shock, especially post-cardiac surgery or when β-receptor downregulation limits dobutamine effect
- Useful in pulmonary hypertension (reduces PVR)
- Longer half-life — effects accumulate, harder to titrate; prolonged hypotension if overdosed
- Renally cleared — dose-reduce in AKI
Phenylephrine
Bolus 50–200 mcg IV | Infusion 10–300 mcg/min
Pure α₁ agonist — vasoconstriction without inotropic effect
Useful in tachycardia-associated shock where noradrenaline’s β₁ effect is undesirable (e.g., HOCM, AF with fast ventricular rate)
Reflex bradycardia — use cautiously in bradycardic patients
Can worsen cardiogenic shock by increasing afterload without supporting cardiac output
| Situation | First agent | Add / escalate to | Avoid |
|---|---|---|---|
| Undifferentiated shock | Noradrenaline | Fluid trial first; escalate based on 6-step framework | — |
| Septic shock (vasodilatory) | Noradrenaline | Terlipressin (refractory); hydrocortisone; adrenaline if inotrope also needed | Excess fluid, dopamine |
| Cardiogenic shock (LV) | Noradrenaline (MAP support) | Dobutamine or milrinone (inotropy); IABP/Impella/VA-ECMO escalation | Dopamine, excessive adrenaline |
| RV failure | Noradrenaline | Milrinone (reduces PVR + inotrope); adrenaline; inhaled iloprost/NO | Vasodilators, aggressive fluid loading in RV dilation |
| Anaphylaxis | Adrenaline 0.5 mg IM | Adrenaline IV infusion; fluids; glucagon if on β-blockers | Any delay to adrenaline |
| Peri-operative / spinal hypotension | Metaraminol 0.5–2 mg IV bolus | Noradrenaline infusion once CVC placed; phenylephrine if bradycardic | — |
| Bradycardic shock | Atropine → isoprenaline infusion | Temporary transvenous pacing | Phenylephrine, metaraminol (worsen bradycardia) |
| LVOTO / HOCM | Phenylephrine + fluid bolus | Esmolol infusion (rate control) | Inotropes, vasodilators, tachycardia-promoting agents |
| Adrenal crisis | Hydrocortisone 100 mg IV + saline | Noradrenaline if MAP not restored | Delaying hydrocortisone for investigations |

Fluid replacement in dehydrated patients
- Resuscitate intravascular volume until perfusion is normalised as above with 20 mL/kg boluses of crystalloid (normal saline preferred)
- Calculate fluid losses (generally at least 10% of body weight if patient is dehydrated and hypotensive, i.e. 70kg patient is depleted of 7L of fluid)
- Subtract from this defecit the amount of fluid already given for resuscitation (e.g. if 2L given during resuscitation, a 70kg patient still requires 5L of fluid)
- Replace this amount over the next 24 hours together with maintenance fluid and ongoing losses
- Use 4:2:1 rule, or add 60mL to their weight for hourly fluid requirement ⇒ 110mL/hr ≈ 2.5L/day
- Total fluid to be replaced is 7.5 L
- Replace half in first 8 hours and remainder in next 16 hours
- 3.75L over 8 hours ≈ 450 mL/h
- 3.75L over 16 hours ≈ 230 mL/h
- Monitor adequacy of replacement by perfusion and vital signs, urine output and electrolyte changes
| Drug | Alpha-1 | Beta-1 | Beta-2 | Dopamine | Effect on SVR | Effect on HR | Effect on CO | Effect on BP |
|---|---|---|---|---|---|---|---|---|
| Phenylephrine | +++ | 0 | 0 | 0 | ↑↑ | ↓ / ↔ | ↓ | ↑↑ |
| Metaraminol | +++ | + (indirect) | 0 | 0 | ↑↑ | ↔ / ↑ | ↔ / ↑ | ↑↑ |
| Vasopressin (V1 agonist) | 0 | 0 | 0 | 0 | ↑↑ | ↔ | ↓ | ↑ |
| Noradrenaline | +++ | ++ | 0 | 0 | ↑↑ | ↑ | ↔ / ↑ | ↑↑ |
| Adrenaline (Low dose) | + | +++ | ++ | 0 | ↓ | ↑ | ↑ | ↔ / ↑ |
| Adrenaline (High dose) | ++ | +++ | ++ | 0 | ↔ / ↑ | ↑ | ↑ | ↑↑ |
| Dopamine (Low dose)* | 0 | + | 0 | ++ | ↔ | ↑ | ↑ | ↑ |
| Dopamine (Moderate dose)* | + | ++ | 0 | ++ | ↑ | ↑ | ↑ | ↑↑ |
| Dopamine (High dose)* | ++ | ++ | 0 | ++ | ↑↑ | ↑ | ↔ / ↑ | ↑↑ |
| Dobutamine | 0 / + | +++ | ++ | 0 | ↓ | ↑ | ↑↑ | ↓ / ↔ / ↑ |
| Isoprenaline | 0 | +++ | +++ | 0 | ↓ | ↑↑ | ↑↑ | ↓ / ↔ |
| Milrinone (PDE inhibitor) | 0 | 0 | 0 | 0 | ↓ | ↔ / ↑ | ↑↑ | ↓ / ↔ / ↑ |
Dexamethasone does not interfere with the cortisol level allowing one to perform an ACTH stimulation test later if indicated